Journal of Immunology Research / 2014 / Article / Tab 1

Review Article

Use of Autoantibodies to Detect the Onset of Breast Cancer

Table 1

Comparison between individual autoantibodies and autoantibody signatures in breast cancer.

TAA
composition
Serum samplesMethodsIndividual autoantibodies PanelRef.
AUCSensitivitySpecificityAUCSensitivitySpecificity

p53, c-myc, HER2, NY-ESO-1, BRCA1,
BRCA2, and MUC1
40 DCIS versus 97 PBC versus 90 HCELISA24; 13; 18; 26; 8; 34; 20% (PBC versus HC)
15; 8; 13; 8; 3; 23; 13% (DCIS versus HC)
96; 97; 94; 94; 91; 92; 98% 64% (PBC versus HC) 45% (DCIS versus HC)85%[26]

p53, p62, c-myc, cyclin B1, survivin, and IMP164 breast cancers versus 346 HCELISA Frequency of AABs to seven cancer-associated antigens:
7.8; 7.8; 18.8; 4.7; 7.8; 7.8% (breast cancer) and 1.4; 2; 1.2; 1.7; 2; 2% (HC)
Frequency of AABs to any seven antigens: 43.8% (breast cancer) and 10.1% (HC)[31, 32]
67–92%85–95%

MUC1, cyclin D1, cathepsin D, p53, HER2, IGFBP-2, and TOPO2α184 late-stage IBC versus 134 HCELISA Frequency of AABs to seven cancer-associated antigens: 20; 8; 5; 10; 13; 14; 7% (breast cancer) and 3; 5; 3; 1; 5; 1; 3% (HC) Frequency of AABs to any p53. HER2. MUC1 and TOPO2α antigens: 31% (breast cancer) [33]
0.48 (p53)0.61 (p53 + HER2)
0.63 (p53 + HER2 + IGFBP-2 + TOPO2α)

ASB-9,
SERAC1, and RELT
Training set: 5 breast cancers versus 5 HCSEREX0.593; 0.642; 0.72741; 47; 53%
(training set)
59; 53; 65% (validation set)
100; 100; 100% (training set)
65; 71; 77% (validation set)
0.86180% (training set)
77% (validation set)
100% (training set)
82.8% (validation set)
[34]
Validation set: 87 breast cancers versus 87 HCELISA

HSP60, MUC1, FKBP52, PPIA, PRDX2, HSP60, and MUC1Training set: 20 breast cancers versus 20 other cancers versus 20 AID versus 20 HCSERPA0.69; 0.69; 0.66; 0.57; 0.59 (HC versus cancer)
0.63; 0.68; 0.66; 0.64; 0.63 (HC versus early-stage PBC)
0.73; 0.70; 0.65; 0.51; 0.56 (HC versus DCIS)
35; 37; 50; 50; 45% (HC versus cancer)
44; 43; 43; 48; 45% (HC versus early-stage PBC)
27; 32; 55; 51; 45% (HC versus DCIS)
87; 88; 87; 87; 86% (HC versus cancer)
86; 87; 90; 89; 87% (HC versus early-stage PBC)
90; 89; 87; 86; 84% (HC versus DCIS)
0.74 (HC versus cancer)
0.73 (HC versus early-stage PBC)
0.80 (HC versus DCIS)
60.5% (HC versus cancer)
55.2% (HC versus early-stage PBC)
72.2% (HC versus DCIS)
77.2% (HC versus cancer)
87.9% (HC versus early-stage PBC)
72.6% (HC versus DCIS)
[27]
Validation set: 82 DCIS versus 60 early-stage PBC versus 93 HCELISA

GAL3, PAK2, PHB2, RACK1, and RUVBL1Training set: 20 cancers (10 DCIS and 10 early-stage PBC) versus 20 BBL versus 20 AID versus 20 HCSERPA0.61; 0.56; 0.55; 0.59; 0.52 (HC versus cancer)
0.67; 0.59; 0.62; 0.61; 0.59 (HC versus early-stage PBC)
0.56; 0.52; 0.50; 0.57; 0.50 (HC versus DCIS)
32; 25; 24; 31; 24% (HC versus cancer)
47; 31; 32; 31; 31% (HC versus early-stage PBC)
24; 27; 18; 29; 18% (HC versus DCIS)
94; 96; 97; 94; 94% (HC versus cancer)
88; 94; 94; 97; 93% (HC versus early-stage PBC)
97; 91; 97; 94; 94% (HC versus DCIS)
0.81 (HC versus cancer)
0.81 (HC versus early-stage PBC)
0.85 (HC versus DCIS)
62–66%
(HC versus cancer)
63–71%
(HC versus early-stage PBC)
73–82%
(HC versus DCIS)
83–87% (HC versus cancer)
81–84% (HC versus early-stage PBC)
74–82% (HC versus DCIS)
[28]
Validation set: 55 DCIS versus 59 early-stage PBC versus 68 HCELISA

p62, p53, c-myc, survivin, p16, cyclin B1, cyclin D1, and CDK2 Training set: 1 cancer versus 4 HCMiniarray Frequency of AABs to eight cancer-associated antigens: 12.2; 12.2; 22; 22; 12.2; 17.1; 17.1; 9.8% (breast cancer) and 1.2; 2.4; 0; 1.2; 2.4; 1.2; 2.4; 1.2% (HC) Frequency of AABs to any eight antigens: 61% (breast cancer) and 11% (HC) [29]
Validation set: 41 cancers versus 82 HCELISA22% (c-myc)100% (c-myc)61%89%

hnRNPF and FTH1 Training set: 5 cancers versus 5 HCSEREX0.725; 0.68684.2; 81.2%60.8; 56.1%0.81691.1%
89.3% (when combined with CA15-3)
72%
93.8% (when combined with CA15-3)
[30]
Validation set: 155 breast cancers versus 155 HC versus 40 others cancersELISA

RBP-Jk, HMGN1, PSRC1, CIRBP, and ECHDC1Training set: 20 DCIS versus 20 early-stage PBCMicroarray 0.57; 0.58; 0.51; 0.51; 0.5462.7; 59.3; 16.9; 80.6; 59.3%57.4; 54.1; 93.4; 31.8; 60.7%0.79483.3–86.1%72.7–75% [35]
Validation set: 61 DCIS versus 59 early-stage PBCELISA

TAA: tumor-associated antigens; AABs: autoantibodies; AUC: area under curve; DCIS: ductal carcinoma in situ; PBC: primary breast cancer; HC: healthy control; AID: autoimmune disease; BBL: benign breast lesions; Ref: references.